Cellectar Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Cellectar Biosciences, Inc. (CLRB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $21.30 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-04
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $21.30, a 71.02% decline from fiscal 2024.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $73.50, a 5344.44% increase from fiscal 2023.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.35.
- Cellectar Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2018 was $191.38, a 68.69% decline from fiscal 2017.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $21.30 10-K · filed 2026-03-04 | |
| 2024-12-31 | $73.50 10-K · filed 2026-03-04 | $2.45 10-K · filed 2025-03-13 |
| 2023-12-31 | $1.35 10-K · filed 2025-03-13 | |
| 2018-12-31 | $191.38 10-K · filed 2020-03-09 | |
| 2017-12-31 | $611.20 10-K · filed 2019-02-26 | $61.12 10-K · filed 2018-03-21 |
| 2016-12-31 | $116.32 10-K · filed 2018-03-21 | |
| 2015-12-31 | $126.10 10-K · filed 2017-03-15 | |
| 2014-12-31 | $196.21 10-K/A · filed 2016-10-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |